Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

This study is testing whether adding blinatumomab — a drug that helps the immune system find and kill cancer cells — before a stem cell transplant improves outcomes for high-risk B-cell acute lymphoblastic leukemia (B-ALL) patients who have already achieved remission with no detectable disease (MRD-negative). **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) using 2022 WHO criteria - Your leukemia is classified as high-risk based on specific genetic or clinical features - Your cancer cells are CD19-positive and BCR-ABL1-negative - You achieved complete remission after initial treatment, with no detectable residual disease (MRD-negative) **You may NOT be eligible if...** - You do not have high-risk features as defined by NCCN guidelines - Your cancer cells are BCR-ABL1-positive - You have not achieved remission after initial treatment Talk to your doctor to see if this trial is right for you.